Iomab-B for the treatment of Refractory and Relapsed Acute Myeloid Leukaemia

Iomab-B is a radio-immunotherapeutic drug developed by Actinium Pharmaceuticals for treatment of refractory and relapsed acute myeloid leukaemia in elderly patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news